Home | UCSF Helen Diller Family Comprehensive Cancer Center

Kevan Shokat, PhD, looks at a digital image of a KRAS Q61h inhibitor with Julius Pampel, a graduate student in Shokat’s lab, at Genentech Hall on the UCSF Mission Bay Campus. Photo by Erin Lubin

UCSF’s Kevan Shokat Wins Stephenson Prize for Cancer Breakthrough

By finding a way to attack the most important human oncogene, KRAS, the UCSF chemical biologist launched a new era in cancer treatment.

J. Michael Bishop, MD (right), with colleagues in 1989. Photo courtesy of UC San Francisco, Library, University Archives

How to Win a Nobel Prize: Advice on Science, San Francisco, and UCSF

Gaze inside the mind of a Nobel laureate who helped revolutionize medicine by revealing cancer’s surprising, at the time, genetic roots.

2026 International Invasive Lobular Carcinoma Symposium

Here’s the Latest Research Lobular Breast Cancer Experts Are Leading

Invasive lobular carcinoma (ILC) is the second most common type of breast cancer but is challenging to detect because of how it spreads in breast tissue. Clinicians and researchers set to gather for the UCSF-cosponsored international invasive lobular carcinoma symposium in San Francisco, Sept. 23 to 25.

From left toright: Kevan Shokat, PhD, winner of the Gamechanger Award; Joseph DeRisi, PhD, winner of the Best Startup Award; Susan Lynch, PhD, winner of the Disruptive Research Award; and Steven Hauser, MD, winner of the Distinguished Lifetime Achievement Award.

UCSF Wins Big, From Gamechangers to Startups to Life Achievement

Four UC San Francisco professors received UC Regents Innovation Awards on Sept. 16. Kevan Shokat, PhD, won the Gamechanger Award which recognizes the most impactful product brought to market.

FDA Approves PET Imaging Agent for Brain Cancer Based on UCSF Data

UC San Francisco study data was instrumental in today’s approval by the Food and Drug Administration (FDA) of a PET imaging agent that helps physicians evaluate gliomas, a form of brain cancer.

Two daraxonrasib pills, which are blue and oval in shape.

New Drug With UCSF Roots Has Revolutionized Pancreatic Cancer Care

More than a decade after UCSF scientists discovered a way to target the once “undruggable” RAS protein, their work has led to an FDA-approved treatment that significantly extends survival for patients with metastatic pancreatic cancer.

This is How Dense Breast Tissue May Lead to Cancer

UC San Francisco researchers trace the beginnings of breast cancer to a dangerous interaction between stiffer tissue, immune cells, and chemicals made by the body that mutate DNA.

Julian Hong, MD, stands outside at UCSF Mission Bay.

Shaping Our AI Future

Julian Hong, MD, discusses opportunities for AI in research and care, and why faculty and trainees will be essential to what comes next.

A pharmacy technician wearing blue latex glove and a surgical mask prepares a dose of the Moderna COVID-19 vaccine.

Why Novel Cancer Vaccine Tested at UCSF Marks New Treatment Era

A personalized mRNA vaccine tested at UC San Francisco has become the first to successfully prevent the return and spread of cancer in late-stage clinical trials. The results could signal a new era of vaccines to treat a range of cancers, says UCSF Professor of Medicine Adil Daud, MD, who led the university’s trial site.